Oramed Pharmaceuticals Inc. has historically built its identity around a platform for orally delivering injectable biologics, most notably oral insulin. Its Protein Oral Delivery (POD™) technology is designed to protect drug molecules and improve absorption through the gastrointestinal tract, potentially replacing injections for large chronic-disease markets. The lead candidate, ORMD-0801, targets type 2 diabetes, while an oral glucagon-like peptide-1 (GLP-1) receptor agonist candidate addresses a fast-growing metabolic-disease segment.
However, after a prior Phase 3 trial missed its primary endpoint, management pivoted toward a subgroup-driven strategy, identifying patient populations—such as those with lower body mass index (BMI) and older demographics—that showed clinically meaningful reductions in HbA1c (a measure of average blood sugar). This reframing, alongside the January 2026 agreement to transfer the POD™ technology to Lifeward while acquiring a 49.99% equity interest, positions Oramed less as a single-asset biotech and more as a strategic investor and platform operator. The medium-term competitive question is whether this diversified model can sustain value creation while the refined oral insulin program pursues validation independently. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Several forward-looking developments could shape investor sentiment. The most important is the data readout from the planned 60-patient U.S. clinical trial for ORMD-0801, which management designed to be cost-efficient and statistically focused on previously identified high-responder subgroups. Positive, reproducible results would materially de-risk the program and support further regulatory dialogue.
Earnings disclosures also matter: ORMP's third-quarter 2026 results are scheduled for November 16, 2026, with full-year fiscal 2026 results expected around March 3, 2027. Beyond financials, investors will watch commentary on portfolio monetization, including anticipated returns from the Scilex investment and associated royalties, as well as any progress integrating the Lifeward position.
On analyst ratings and price targets, the consensus profile has firmed modestly. Aggregate one-year price targets compiled by Fintel rose to $7.14 per share in September 2026, up roughly 12% from the prior $6.38 estimate, within a narrow range of $7.07 to $7.35. In October 2026, Weiss Ratings upgraded ORMP to a "Buy" rating. Coverage remains limited, so individual target revisions can carry outsized weight for a stock of this size.
Oramed operates at the intersection of oral-biologics innovation and the metabolic-disease market, where demand for convenient, non-injectable therapies for diabetes and obesity remains structurally strong. The global injectable drug-delivery market is large, and oral alternatives could capture share if clinical and regulatory hurdles are cleared. Yet this is a capital-intensive, high-attrition arena, and the broader interest-rate environment directly affects both the discounting of future cash flows and the availability of growth capital for small-cap developers.
Regulatory climate is another pivotal force. FDA feedback on the refined trial design and any future pathway toward a Biological License Application (BLA)—the submission required to seek marketing approval for a biologic product—will shape timelines. Geopolitical and funding conditions also matter, given Oramed's earlier partnership efforts in China and its reliance on a diversified investment portfolio whose mark-to-market value can swing with biotech sector sentiment.
Looking toward 2026 and beyond, Oramed's trajectory hinges on two parallel engines. First, the oral insulin program must demonstrate that a refined, subgroup-targeted approach can convert earlier signals into regulatory-grade evidence. Second, the investment portfolio and the Lifeward stake must continue generating returns that fund research and development (R&D) without excessive shareholder dilution.
Long-term themes include the durability of margins and cost structure as the company balances clinical spending against portfolio income, the pace of technology transition from injection-based to oral delivery, and competitive threats from larger players advancing oral GLP-1 and oral insulin programs. Capital-allocation priorities—buybacks, a contemplated one-time dividend, and selective investments—will increasingly define how the market values the company. Thin analyst coverage means consensus expectations can shift quickly, and externally published price targets should be read as analyst views rather than forecasts from this article. From what I see, I'm watching this closely for signs of execution on the new strategy.
In my view, Tickeron's AI Trend Prediction Engine has been a useful addition to my routine when assessing stocks like this one. It provides data-driven forecasts on potential trends over the coming weeks or months, helping me cross-check fundamental views with quantitative signals without replacing core analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Aroon Indicator for ORMP entered a downward trend on November 16, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 184 similar instances where the Aroon Indicator formed such a pattern. In 153 of the 184 cases the stock moved lower. This puts the odds of a downward move at 83%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORMP as a result. In 66 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for ORMP turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 39 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ORMP's RSI Indicator exited the oversold zone, 25 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
ORMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. ORMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.506) is normal, around the industry mean (3.596). P/E Ratio (0.910) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.259) settles around the average of (131.631) among similar stocks. P/S Ratio (90.909) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company which engages in pharmaceutical preparations
Industry Biotechnology